Mounjaro vs Zepbound: same drug and two different sets of rules
Mounjaro and Zepbound are the same molecule from the same maker, tirzepatide, in the same pen. Mounjaro is approved for type 2 diabetes and Zepbound for weight and sleep apnea. That one line on the label decides your prior authorization, your Medicare answer and whether a cash price exists at all.
Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea. Everything else is the same: tirzepatide, made by Eli Lilly, at the same strengths in the same pens and vials. The table below is what changes with the indication.
What is actually different
| Mounjaro | Zepbound | |
|---|---|---|
| Molecule | Tirzepatide | Tirzepatide |
| Approved for | Type 2 diabetes | Chronic weight management, and moderate-to-severe obstructive sleep apnea |
| What the label says about the target dose | No maintenance list. A ceiling, and each step up is conditional on needing more glycemic control | A named maintenance list, and a lower one if a patient does not tolerate it |
| Medicare | Covered as a diabetes drug | Not covered for weight loss under Part D, and covered only for the sleep apnea indication. One CMS demonstration pays a flat $50 a month, and it names the KwikPen only |
| Cash routes on our chart | None. Mounjaro is filled at a pharmacy on a diabetes benefit | Several, and they are in the chart |
The full ladders sit on the pages that own them: Mounjaro dosing and Zepbound dosing. The device is the same for both, and it is covered on the KwikPen page.
Why one molecule carries two names
Lilly ran two trial programs. The SURPASS studies tested tirzepatide in type 2 diabetes and produced the Mounjaro approval in May 2022. The SURMOUNT studies tested it in people with obesity and produced the Zepbound approval in November 2023.
Novo Nordisk did the same thing with semaglutide, which is sold as Ozempic for diabetes and Wegovy for weight. Two names let a maker sell into two benefit categories that price and cover the same drug differently.
The insurance difference is most of the difference
Diabetes drugs sit on almost every formulary. Weight-management drugs do not, and where they do the prior authorization asks for more: a BMI threshold, a comorbidity, sometimes months of documented lifestyle change, sometimes a failed attempt on another drug first. See what 20 insurers put in writing.
Two practical consequences. If you have type 2 diabetes, the Mounjaro request is the one your plan is set up to say yes to. If you do not, asking for Mounjaro is asking for an off-label prescription, which is a different conversation with a different success rate.
What it costs if the plan says no
Cash-pay programs publish prices for Zepbound. None publishes one for Mounjaro, because Mounjaro is filled at a pharmacy on a diabetes benefit. Every Zepbound route on the chart carries the price that program publishes, checked August 31, 2026.
Questions people ask
Is the medicine in a Mounjaro pen the same as in a Zepbound pen?
Yes. Both labels describe tirzepatide at the same strengths in the same presentations: a single-dose pen, a single-dose vial, a multi-dose vial and a KwikPen holding four weekly doses.
Can my prescriber move me from one to the other at the same dose?
The strengths line up, so a switch does not restart the ladder. What restarts is the insurance: a new prescription is a new claim, judged against the criteria for the new label, and an approval on one does not carry to the other. Your prescriber writes the dose.
Which one should I ask for?
That is a clinical decision and it belongs with your prescriber. What each choice does to the bill is this. With a type 2 diabetes diagnosis, Mounjaro is the request insurers are built to approve. Without one, Zepbound is the on-label request and the only one of the two with published cash routes if the plan refuses.
Does Medicare cover either?
Part D covers Mounjaro for diabetes. It does not cover any drug for weight loss, so Zepbound is only covered for the sleep apnea indication. Separately, the Medicare GLP-1 Bridge pays a flat $50 a month for the Zepbound KwikPen, and not the vials or single-dose pens, through December 31, 2027. Full detail on the Medicare page.
Sources
Evidence checked August 31, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. No clinician reviews these pages. What that means.
- The Mounjaro indication, the absence of a maintenance list and the escalation ruleFDA prescribing information for Mounjaro (DailyMed, revised August 2026)
- The Zepbound indications, the maintenance list and the shared presentations including the four-dose KwikPenFDA prescribing information for Zepbound (DailyMed, revised August 2026)
This week's best deals
Compare these programs
